NantCell, the immuno-oncology arm of Dr. Patrick Soon-Shiong’s sprawling NantWorks umbrella company, has just raised another $57 million, according to a regulatory filing. There are 125 investors listed on this equity raise.
NantCell was launched a year ago, with news of a licensing agreement with Amgen. It acquired the rights to develop and commercialize monoclonal antibody AMG 479, ganitumab, which was previously in Phase 3 development at the biopharma giant. The therapeutic targets Type 1 insulin-like growth factor receptor, which has been a promising cancer therapy target.
In March, it teamed up with San Diego-based Sorrento Therapeutics – acquiring a next-gen version of Abraxane in a deal worth up to $1.3 billion. About $100 million of that was paid as NantCell Equity.
The company’s had two notable fundraises in the past year – $100 million in September, and $75 million in June.
However, NantCell still has no website, and remains as mysterious as most subsidiaries in Soon-Shiong’s healthcare empire. The company has yet to respond to an inquiry regarding the fundraise.
[Photo courtesy of Getty Images]